QLS5132 + olaparib + bevacizumab

QLS5132 + olaparib + bevacizumab is a combination therapy regimen being developed by Qilu Pharmaceutical for the treatment of advanced solid tumors, including ovarian, gastric, endometrial, and non-small cell lung cancers. QLS5132 is an antibody-drug conjugate (ADC) targeting Claudin-6 (CLDN6), a protein frequently overexpressed in solid tumors but with limited expression in normal adult tissues. The ADC consists of a humanized anti-CLDN6 hIgG1 antibody conjugated to QLS6916, a proprietary topoisomerase-1 inhibitor payload, via a hydrophilic cleavable linker. Olaparib is a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, which are essential for DNA repair; its inclusion aims to exploit synthetic lethality and potentially sensitize tumor cells to the DNA-damaging effects of the ADC payload. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis to restrict tumor blood supply and improve drug delivery. This triplet combination is currently being evaluated in a Phase Ib/II clinical trial to assess safety, tolerability, and preliminary efficacy.